3
Clinical Trials associated with DavelizomibA Phase I Study of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody.
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.
[Translation] Phase I clinical study on tolerability and pharmacokinetics of TQB3602 capsules
评价复发难治的多发性骨髓瘤受试者单次或多次口服TQB3602胶囊的安全性和耐受性,确定最大耐受剂量和剂量限制性毒性,为后续临床试验给药方案的制定提供依据。评价复发难治的多发性骨髓瘤受试者单次或多次口服TQB3602胶囊的人体药代动力学特征,初步评价TQB3602胶囊的疗效。
[Translation] To evaluate the safety and tolerability of TQB3602 capsules taken orally once or multiple times in subjects with relapsed or refractory multiple myeloma, determine the maximum tolerated dose and dose-limiting toxicity, and provide a basis for the formulation of dosing regimens for subsequent clinical trials. To evaluate the pharmacokinetic characteristics of TQB3602 capsules taken orally once or multiple times in subjects with relapsed or refractory multiple myeloma, and preliminarily evaluate the efficacy of TQB3602 capsules.
100 Clinical Results associated with Davelizomib
100 Translational Medicine associated with Davelizomib
100 Patents (Medical) associated with Davelizomib
100 Deals associated with Davelizomib